


SCARD Pool report for 01-01-2011 to 31-12-2011

| | | | |
|---------------------|-----------------------------|--------|---------|
| Participants | Doctors | 387 | |
| | Patients | 38,570 | |
| Specimens | New lesions | 68,645 | 84.91% |
| | Previously biopsied lesions | 12,200 | 15.09% |
| | Total lesions | 80,845 | 100.00% |

Breakdown of new versus previously biopsied specimens


| | |
|--|--------|
| Percentage of new lesions tested which were malignant | 60.15% |
| Percentage of Definitively excised lesions that were malignant | 73.12% |
| Lesions tested to find one melanoma (NNT) | 6.82 |
| Percentage of lesions tested for NMSC which were NMSC | 73.15% |
| Ratio of New BCCs : New Melanomas | 12:1 |

Accuracy
Diagnostic sensitivity

| | |
|-----------|------------------|
| Melanomas | 65.56% of 1,684 |
| All NMSC | 94.49% of 38,916 |
| BCCs | 87.62% of 20,070 |
| SCCs | 80.59% of 18,705 |

Positive predictive value


| | |
|-----------|------------------|
| Melanomas | 41.69% of 2,648 |
| All NMSC | 80.04% of 45,937 |
| BCCs | 38.28% of 45,937 |
| SCCs | 65.13% of 23,147 |

Adequacy
Percentage of definitively managed malignant cases where surgical margins were adequate

| | |
|---------------------------|------------------|
| BCC | 87.55% of 14,084 |
| IEC/Bowens disease | 84.98% of 3,721 |
| SCC | 87.43% of 5,220 |
| Keratoacanthoma | 93.55% of 1,349 |
| Melanoma - in situ | 82.21% of 1,034 |
| Melanoma - invasive | 85.86% of 396 |
| Melanoma - invasive > 1mm | 47.37% of 38 |
| Other malignant | 72.73% of 66 |

Lesion Breakdown
Histological Diagnosis

| | | |
|-----------------------------|--------|--------|
| BCC (unspecified type) | 4,696 | 6.83% |
| BCC - Superficial | 5,062 | 7.36% |
| BCC - Nodular/Solid | 7,130 | 10.37% |
| BCC - Aggressive | 3,182 | 4.63% |
| IEC/Bowens disease | 10,235 | 14.89% |
| SCC | 6,771 | 9.85% |
| Keratoacanthoma | 1,699 | 2.47% |
| Pinkus Fibroepithelioma | 1 | 0.00% |
| Merkel cell tumour | 7 | 0.01% |
| Other malignant | 84 | 0.12% |
| NMSC Metastasis | 5 | 0.01% |
| Melanoma - in situ | 1,063 | 1.55% |
| Melanoma - invasive | 494 | 0.72% |
| Melanoma - invasive > 1mm | 89 | 0.13% |
| Melanoma - metastasis | 38 | 0.06% |
| MELTUMP | 44 | 0.06% |
| Naevus - other | 3,583 | 5.21% |
| Naevus - dysplastic/Clark | 3,425 | 4.98% |
| Naevus - blue | 211 | 0.31% |
| Naevus - Spitz/Reed | 79 | 0.11% |
| Naevus - Compound | 0 | 0% |
| Solar keratosis | 6,024 | 8.76% |
| Solar lentigo | 990 | 1.44% |
| Seborrhoeic keratosis | 4,482 | 6.52% |
| Lentigo Simplex | 0 | 0% |
| Lichenoid keratosis (LPLK) | 897 | 1.30% |
| Dermatofibroma | 536 | 0.78% |
| Sebaceous gland hyperplasia | 136 | 0.20% |
| Benign cyst | 1,150 | 1.67% |
| Other benign | 5,314 | 7.73% |
| Histology Pending | 92 | 0.13% |



Procedures
Definitive Surgical Management used to exclude melanoma

| | | |
|-----------------------|-------|--------|
| Ellipse | 4,153 | 90.78% |
| Flap | 89 | 1.95% |
| Graft - SSG | 10 | 0.22% |
| Graft - FTSG | 15 | 0.33% |
| No Closure | 1 | 0.02% |
| Shave/Saucerisation | 151 | 3.30% |
| Curettage & Cautery | 98 | 2.14% |
| Liquid N2 freeze/thaw | 2 | 0.04% |
| PDT | 0 | 0% |
| Imiquimod | 0 | 0% |
| 5 FU cream | 0 | 0% |
| GP referral | 4 | 0.09% |
| Specialist referral | 22 | 0.48% |
| Other | 30 | 0.66% |

Biopsy used to exclude melanoma

| | | |
|-----------------|-------|--------|
| Punch - sample | 913 | 11.22% |
| Shave - sample | 1,826 | 22.44% |
| Incisional | 67 | 0.82% |
| Punch - removal | 1,068 | 13.12% |
| Shave - removal | 1,832 | 22.51% |
| Excisional | 2,319 | 28.49% |
| Curettage | 105 | 1.29% |
| Other | 7 | 0.09% |

Breakdown of definitive management procedures for malignant conditions

| | | |
|-----------------------|--------|--------|
| Ellipse | 22,676 | 67.15% |
| Flap | 3,147 | 9.32% |
| Graft - SSG | 237 | 0.70% |
| Graft - FTSG | 627 | 1.86% |
| No Closure | 102 | 0.30% |
| Shave/Saucerisation | 368 | 1.09% |
| Curettage & Cautery | 4,211 | 12.47% |
| Liquid N2 freeze/thaw | 493 | 1.46% |
| PDT | 128 | 0.38% |
| Imiquimod | 327 | 0.97% |
| 5 FU cream | 343 | 1.02% |
| GP referral | 53 | 0.16% |
| Specialist referral | 803 | 2.38% |
| Other | 129 | 0.38% |

Breakdown of definitive management procedures for benign conditions

| | | |
|-----------------------|-------|--------|
| Ellipse | 6,188 | 80.17% |
| Flap | 79 | 1.02% |
| Graft - SSG | 10 | 0.13% |
| Graft - FTSG | 7 | 0.09% |
| No Closure | 5 | 0.06% |
| Shave/Saucerisation | 629 | 8.15% |
| Liquid N2 freeze/thaw | 165 | 2.14% |
| 5 FU cream | 53 | 0.69% |
| GP referral | 4 | 0.05% |
| Specialist referral | 31 | 0.40% |
| Other | 115 | 1.49% |

Procedures (continued)

Percentage of procedures/closures that were complex

| | |
|--|------------------|
| Complex Closures | 10.62% of 40,554 |
| Complex Closures (inc Curettage & Cautery) | 9.53% of 45,186 |

Locations

Breakdown of melanomas by location and percentage melanomas of total lesions at that location

| | | |
|---------------|-----|-----------------|
| Nose | 15 | 0.35% of 4,345 |
| Lip | 1 | 0.09% of 1,145 |
| Ear | 39 | 1.40% of 2,781 |
| Eyelid | 4 | 0.57% of 697 |
| Other face | 185 | 1.54% of 12,048 |
| Scalp | 38 | 1.88% of 2,025 |
| Neck | 60 | 1.75% of 3,436 |
| Shoulder | 126 | 3.96% of 3,183 |
| Chest | 81 | 2.02% of 4,013 |
| Abdomen | 41 | 4.15% of 988 |
| Genitalia | 0 | 0% of 93 |
| Back | 534 | 5.35% of 9,976 |
| Buttock | 8 | 4.49% of 178 |
| Arm | 150 | 3.72% of 4,027 |
| Forearm | 120 | 2.23% of 5,375 |
| Hand Dorsal | 2 | 0.07% of 2,771 |
| Hand Palmar | 1 | 5.88% of 17 |
| Finger Dorsal | 0 | 0% of 470 |
| Finger Nail | 1 | 100.00% of 1 |
| Finger Palmar | 0 | 0% of 8 |
| Thigh | 80 | 4.22% of 1,897 |
| Leg | 183 | 2.16% of 8,465 |
| Foot Dorsal | 8 | 1.56% of 512 |
| Foot Plantar | 0 | 0% of 49 |
| Toe Dorsal | 3 | 3.53% of 85 |
| Toe Nail | 1 | 100.00% of 1 |
| Toe Plantar | 2 | 18.18% of 11 |
| Palm Or Sole | 0 | 0% of 15 |

